{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:59:44Z","timestamp":1792897184959,"version":"4.5.0"},"reference-count":380,"publisher":"The Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteoclasts have traditionally been associated exclusively with catabolic functions that are a prerequisite for bone resorption. However, emerging data suggest that osteoclasts also carry out functions that are important for optimal bone formation and bone quality. Moreover, recent findings indicate that osteoclasts have different subtypes depending on their location, genotype, and possibly in response to drug intervention.<\/jats:p><jats:p>The aim of the current review is to describe the subtypes of osteoclasts in four different settings: 1) physiological, in relation to turnover of different bone types; 2) pathological, as exemplified by monogenomic disorders; 3) pathological, as identified by different disorders; and 4) in drug-induced situations.<\/jats:p><jats:p>The profiles of these subtypes strongly suggest that these osteoclasts belong to a heterogeneous cell population, namely, a diverse macrophage-associated cell type with bone catabolic and anabolic functions that are dependent on both local and systemic parameters. Further insight into these osteoclast subtypes may be important for understanding cell\u2013cell communication in the bone microenvironment, treatment effects, and ultimately bone quality.<\/jats:p>","DOI":"10.1210\/er.2010-0006","type":"journal-article","created":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T18:26:07Z","timestamp":1297103167000},"page":"31-63","source":"Crossref","is-referenced-by-count":213,"title":["Osteoclast Activity and Subtypes as a Function of Physiology and Pathology\u2014Implications for Future Treatments of Osteoporosis"],"prefix":"10.1210","volume":"32","author":[{"given":"K.","family":"Henriksen","sequence":"first","affiliation":[{"name":"Nordic Bioscience A\/S (K.H., M.A.K.), DK-2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bollerslev","sequence":"first","affiliation":[{"name":"Section of Endocrinology (J.B.), Department of Medicine, Rikshospitalet, Oslo University Hospital and the University of Oslo, 0450 Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Everts","sequence":"first","affiliation":[{"name":"Department Oral Cell Biology (V.E.), Academic Centre of Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Research Institute Move, 1066 EA Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Karsdal","sequence":"first","affiliation":[{"name":"Nordic Bioscience A\/S (K.H., M.A.K.), DK-2730 Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071611584947100_B1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00439-008-0583-8","article-title":"Advances in osteoclast biology resulting from the study of osteopetrotic mutations","volume":"124","author":"Segovia-Silvestre","year":"2009","journal-title":"Hum Genet"},{"key":"2020071611584947100_B2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.bbadis.2009.05.004","article-title":"Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions","volume":"1792","author":"Everts","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2020071611584947100_B3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/jbmr.070109","article-title":"Are nonresorbing osteoclasts sources of bone anabolic activity?","volume":"22","author":"Karsdal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1096\/fasebj.13.10.1219","article-title":"Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone","volume":"13","author":"Everts","year":"1999","journal-title":"FASEB J"},{"key":"2020071611584947100_B5","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1600-0714.1983.tb00337.x","article-title":"The origin of osteoclasts: evidence, clinical implications and investigative challenges of an extra-skeletal source","volume":"12","author":"Marks","year":"1983","journal-title":"J Oral Pathol"},{"key":"2020071611584947100_B6","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00198-009-0904-3","article-title":"Is bone quality associated with collagen age?","volume":"20","author":"Leeming","year":"2009","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00198-006-0298-4","article-title":"Osteoclasts prefer aged bone","volume":"18","author":"Henriksen","year":"2007","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B8","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0002-9440(10)62269-9","article-title":"Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption","volume":"166","author":"Karsdal","year":"2005","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.molmed.2004.12.004","article-title":"Osteoclast-derived activity in the coupling of bone formation to resorption","volume":"11","author":"Martin","year":"2005","journal-title":"Trends Mol Med"},{"key":"2020071611584947100_B10","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1196\/annals.1346.043","article-title":"Mechanisms involved in skeletal anabolic therapies","volume":"1068","author":"Martin","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"2020071611584947100_B11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbrc.2007.11.168","article-title":"Osteoclasts secrete non-bone derived signals that induce bone formation","volume":"366","author":"Karsdal","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071611584947100_B12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cmet.2006.05.012","article-title":"Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis","volume":"4","author":"Zhao","year":"2006","journal-title":"Cell Metab"},{"key":"2020071611584947100_B13","doi-asserted-by":"crossref","first-page":"20764","DOI":"10.1073\/pnas.0805133106","article-title":"Regulation of bone formation by osteoclasts involves Wnt\/BMP signaling and the chemokine sphingosine-1-phosphate","volume":"105","author":"Pederson","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B14","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.bone.2009.03.671","article-title":"Local communication on and within bone controls bone remodeling","volume":"44","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"2020071611584947100_B16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/er.2006-0029","article-title":"Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease","volume":"28","author":"Chavassieux","year":"2007","journal-title":"Endocr Rev"},{"key":"2020071611584947100_B17","first-page":"437","article-title":"Resorption precedes formative activity","volume":"15","author":"Takahashi","year":"1964","journal-title":"Surg Forum"},{"key":"2020071611584947100_B18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/206489a0","article-title":"Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling","volume":"206","author":"Hattner","year":"1965","journal-title":"Nature"},{"key":"2020071611584947100_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0221-8747(82)90002-9","article-title":"The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis","volume":"4","author":"Parfitt","year":"1982","journal-title":"Metab Bone Dis Relat Res"},{"key":"2020071611584947100_B20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF01621884","article-title":"Hormones in the coupling of bone resorption and formation","volume":"3","author":"Martin","year":"1993","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B21","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1210\/en.2003-0717","article-title":"Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption","volume":"144","author":"Nakamura","year":"2003","journal-title":"Endocrinology"},{"key":"2020071611584947100_B22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat Rev Genet"},{"key":"2020071611584947100_B23","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/nrd916","article-title":"Discoveries, drugs and skeletal disorders","volume":"1","author":"Goltzman","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"2020071611584947100_B24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1042\/CS20060046","article-title":"New mechanisms and targets in the treatment of bone fragility","volume":"112","author":"Martin","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"2020071611584947100_B25","first-page":"244","article-title":"Epidemiology of osteoporotic fractures","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Harvey","year":"2006","edition":"6th ed."},{"key":"2020071611584947100_B26","first-page":"365","volume-title":"R\u00f6ntgenbilder einer seltenen Knockenerkrankung","author":"Albers-Sch\u00f6nberg","year":"1904","edition":"5th ed."},{"key":"2020071611584947100_B27","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1056\/NEJMra040952","article-title":"Osteopetrosis","volume":"351","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet"},{"key":"2020071611584947100_B29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ajhg.2008.06.015","article-title":"Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations","volume":"83","author":"Guerrini","year":"2008","journal-title":"Am J Hum Genet"},{"key":"2020071611584947100_B30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0002-9440(10)61221-7","article-title":"Osteoclasts from patients with autosomal dominant osteopetrosis type I (ADOI) caused by a T253I mutation in LRP5 are normal in vitro, but have decreased resorption capacity in vivo","volume":"167","author":"Henriksen","year":"2005","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1196\/annals.1346.015","article-title":"Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation","volume":"1068","author":"Glass","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"2020071611584947100_B32","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00198-006-0286-8","article-title":"Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases","volume":"18","author":"Henriksen","year":"2007","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B33","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2353\/ajpath.2007.060834","article-title":"Osteoclasts: what do they do and how do they do it?","volume":"170","author":"Teitelbaum","year":"2007","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B34","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1242\/dev.122.10.3151","article-title":"Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis","volume":"122","author":"Hayman","year":"1996","journal-title":"Development"},{"key":"2020071611584947100_B35","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1073\/pnas.80.9.2752","article-title":"Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification","volume":"80","author":"Sly","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B36","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"2020071611584947100_B37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/77131","article-title":"Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis","volume":"25","author":"Frattini","year":"2000","journal-title":"Nat Genet"},{"key":"2020071611584947100_B38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0092-8674(00)81169-1","article-title":"MMP-9\/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes","volume":"93","author":"Vu","year":"1998","journal-title":"Cell"},{"key":"2020071611584947100_B39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(01)00206-9","article-title":"Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man","volume":"104","author":"Kornak","year":"2001","journal-title":"Cell"},{"key":"2020071611584947100_B40","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nm842","article-title":"Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human","volume":"9","author":"Chalhoub","year":"2003","journal-title":"Nat Med"},{"key":"2020071611584947100_B41","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2007-979005","article-title":"Receptors of calciotropic hormones","volume":"29","author":"Findlay","year":"1997","journal-title":"Horm Metab Res"},{"key":"2020071611584947100_B42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.bone.2007.08.029","article-title":"Genetics, pathogenesis and complications of osteopetrosis","volume":"42","author":"Del Fattore","year":"2008","journal-title":"Bone"},{"key":"2020071611584947100_B43","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1242\/jcs.108.8.2729","article-title":"The osteoclast clear zone is a specialized cell-extracellular matrix adhesion structure","volume":"108","author":"V\u00e4\u00e4n\u00e4nen","year":"1995","journal-title":"J Cell Sci"},{"key":"2020071611584947100_B44","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Exp Hematol"},{"key":"2020071611584947100_B45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"2020071611584947100_B46","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1083\/jcb.200611083","article-title":"Syk, c-Src, the \u03b1v\u03b23 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption","volume":"176","author":"Zou","year":"2007","journal-title":"J Cell Biol"},{"key":"2020071611584947100_B47","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1074\/jbc.M608572200","article-title":"The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor","volume":"282","author":"Meadows","year":"2007","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B48","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1073\/pnas.091479298","article-title":"Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family","volume":"98","author":"Motyckova","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1359\/jbmr.2000.15.3.451","article-title":"The microphthalmia transcription factor regulates expression of the tartrate-resistant acid phosphatase gene during terminal differentiation of osteoclasts","volume":"15","author":"Luchin","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B50","doi-asserted-by":"crossref","first-page":"39295","DOI":"10.1074\/jbc.M010999200","article-title":"Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption","volume":"276","author":"Zhao","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B51","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"2020071611584947100_B52","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1126\/science.2528207","article-title":"Osteoclastic bone resorption by a polarized vacuolar proton pump","volume":"245","author":"Blair","year":"1989","journal-title":"Science"},{"key":"2020071611584947100_B53","doi-asserted-by":"crossref","first-page":"C1315","DOI":"10.1152\/ajpcell.1991.260.6.C1315","article-title":"Passive chloride permeability charge coupled to H(+)-ATPase of avian osteoclast ruffled membrane","volume":"260","author":"Blair","year":"1991","journal-title":"Am J Physiol"},{"key":"2020071611584947100_B54","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1083\/jcb.101.6.2210","article-title":"Cell-mediated extracellular acidification and bone resorption: evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border","volume":"101","author":"Baron","year":"1985","journal-title":"J Cell Biol"},{"key":"2020071611584947100_B55","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S8756-3282(99)00278-1","article-title":"The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc\/oc) mutants","volume":"26","author":"Scimeca","year":"2000","journal-title":"Bone"},{"key":"2020071611584947100_B56","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/70563","article-title":"Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification","volume":"23","author":"Li","year":"1999","journal-title":"Nat Genet"},{"key":"2020071611584947100_B57","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1093\/hmg\/9.13.2059","article-title":"Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis","volume":"9","author":"Kornak","year":"2000","journal-title":"Hum Mol Genet"},{"key":"2020071611584947100_B58","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0002-9440(10)63712-1","article-title":"Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II","volume":"164","author":"Henriksen","year":"2004","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/nature06907","article-title":"The Cl(\u2212)\/H(+) antiporter ClC-7 is the primary chloride permeation pathway in lysosomes","volume":"453","author":"Graves","year":"2008","journal-title":"Nature"},{"key":"2020071611584947100_B60","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1126\/science.1188072","article-title":"Lysosomal pathology and osteopetrosis upon loss of H+-driven lysosomal Cl\u2212 accumulation","volume":"328","author":"Weinert","year":"2010","journal-title":"Science"},{"key":"2020071611584947100_B61","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1073\/pnas.0811682106","article-title":"Targeted disruption of the Cl\u2212\/HCO3\u2212 exchanger Ae2 results in osteopetrosis in mice","volume":"106","author":"Josephsen","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B62","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1096\/fj.08-122598","article-title":"Ae2a,b-Deficient mice exhibit osteopetrosis of long bones but not of calvaria","volume":"23","author":"Jansen","year":"2009","journal-title":"FASEB J"},{"key":"2020071611584947100_B63","doi-asserted-by":"crossref","first-page":"16934","DOI":"10.1073\/pnas.0808763105","article-title":"HCO3\u2212\/Cl\u2212 anion exchanger SLC4A2 is required for proper osteoclast differentiation and function","volume":"105","author":"Wu","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B64","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":"Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification","volume":"271","author":"Bossard","year":"1996","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B65","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.1073\/pnas.95.23.13453","article-title":"Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice","volume":"95","author":"Saftig","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B66","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","article-title":"Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization","volume":"14","author":"Gowen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B67","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1359\/jbmr.1999.14.11.1902","article-title":"Determination of bone markers in pycnodysostosis: effects of cathepsin K deficiency on bone matrix degradation","volume":"14","author":"Nishi","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1359\/jbmr.2002.17.1.77","article-title":"The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation","volume":"17","author":"Everts","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B69","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1359\/JBMR.050905","article-title":"Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification","volume":"21","author":"Henriksen","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B70","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1359\/jbmr.060614","article-title":"Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone","volume":"21","author":"Everts","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B71","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bone.2004.06.002","article-title":"The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula","volume":"35","author":"Shorey","year":"2004","journal-title":"Bone"},{"key":"2020071611584947100_B72","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1126\/science.276.5310.270","article-title":"Removal of osteoclast bone resorption products by transcytosis","volume":"276","author":"Salo","year":"1997","journal-title":"Science"},{"key":"2020071611584947100_B73","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1126\/science.276.5310.266","article-title":"Trafficking of matrix collagens through bone-resorbing osteoclasts","volume":"276","author":"Nesbitt","year":"1997","journal-title":"Science"},{"key":"2020071611584947100_B74","first-page":"1","article-title":"General principles of bone biology","volume-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","author":"Baron","year":"2005","edition":"5th ed."},{"key":"2020071611584947100_B75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1210\/edrv-10-1-45","article-title":"Autosomal dominant osteopetrosis: bone metabolism and epidemiological, clinical, and hormonal aspects","volume":"10","author":"Bollerslev","year":"1989","journal-title":"Endocr Rev"},{"key":"2020071611584947100_B76","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00223-005-0289-z","article-title":"Calvarial osteoclasts express a higher level of tartrate-resistant acid phosphatase than long bone osteoclasts and activation does not depend on cathepsin K or L activity","volume":"79","author":"Perez-Amodio","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B77","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/excr.2002.5612","article-title":"Osteoclasts from mice deficient in tartrate-resistant acid phosphatase have altered ruffled borders and disturbed intracellular vesicular transport","volume":"279","author":"Hollberg","year":"2002","journal-title":"Exp Cell Res"},{"key":"2020071611584947100_B78","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s00223-007-9032-2","article-title":"Altered collagen in tartrate-resistant acid phosphatase (TRAP)-deficient mice: a role for TRAP in bone collagen metabolism","volume":"80","author":"Roberts","year":"2007","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B79","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bone.2008.05.009","article-title":"Differences in matrix composition between calvaria and long bone in mice suggest differences in biomechanical properties and resorption: special emphasis on collagen","volume":"43","author":"van den Bos","year":"2008","journal-title":"Bone"},{"key":"2020071611584947100_B80","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1083\/jcb.151.4.879","article-title":"Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones","volume":"151","author":"Engsig","year":"2000","journal-title":"J Cell Biol"},{"key":"2020071611584947100_B81","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jemt.10374","article-title":"Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities","volume":"61","author":"Delaiss\u00e9","year":"2003","journal-title":"Microsc Res Tech"},{"key":"2020071611584947100_B82","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0940-9602(01)80180-1","article-title":"An ultrastructural study of osteoclasts and chondroclasts in poorly calcified mandible induced by high doses of strontium diet to fetal mice","volume":"183","author":"Shibata","year":"2001","journal-title":"Ann Anat"},{"key":"2020071611584947100_B83","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/art.1780270902","article-title":"Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint","volume":"27","author":"Bromley","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B84","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.joca.2008.01.014","article-title":"Should subchondral bone turnover be targeted when treating osteoarthritis?","volume":"16","author":"Karsdal","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"2020071611584947100_B85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ncprheum0505","article-title":"Bone, not cartilage, should be the major focus in osteoarthritis","volume":"3","author":"Mansell","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2020071611584947100_B86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tcb.2003.12.003","article-title":"Matrix remodeling during endochondral ossification","volume":"14","author":"Ortega","year":"2004","journal-title":"Trends Cell Biol"},{"key":"2020071611584947100_B87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"2020071611584947100_B88","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1073\/pnas.87.12.4828","article-title":"Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op\/op) mouse","volume":"87","author":"Wiktor-Jedrzejczak","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B89","first-page":"1049","article-title":"Correction by CSF-1 of defects in the osteopetrotic op\/op mouse suggests local, developmental, and humoral requirements for this growth factor","volume":"19","author":"Wiktor-Jedrzejczak","year":"1991","journal-title":"Exp Hematol"},{"key":"2020071611584947100_B90","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B91","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/9467","article-title":"VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation","volume":"5","author":"Gerber","year":"1999","journal-title":"Nat Med"},{"key":"2020071611584947100_B92","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1242\/jcs.108.12.3649","article-title":"Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones","volume":"108","author":"Blavier","year":"1995","journal-title":"J Cell Sci"},{"key":"2020071611584947100_B93","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jbmr.5650060509","article-title":"Inhibiting and stimulating effects of TGF-\u03b2 1 on osteoclastic bone resorption in fetal mouse bone organ cultures","volume":"6","author":"Dieudonn\u00e9","year":"1991","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B94","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1073\/pnas.90.10.4485","article-title":"Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts","volume":"90","author":"Lowe","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B95","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00223-008-9185-7","article-title":"Characterization of the bone phenotype in ClC-7-deficient mice","volume":"83","author":"Neutzsky-Wulff","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B96","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/8756-3282(89)90142-7","article-title":"Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types","volume":"10","author":"Bollerslev","year":"1989","journal-title":"Bone"},{"key":"2020071611584947100_B97","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/8756-3282(93)90316-3","article-title":"Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis","volume":"14","author":"Bollerslev","year":"1993","journal-title":"Bone"},{"key":"2020071611584947100_B98","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s002239900548","article-title":"Chondroclasts and osteoclasts in bones of young rats: comparison of ultrastructural and functional features","volume":"63","author":"Nordahl","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B99","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jmicro\/52.6.493","article-title":"Osteoclast differentiation at growth plate cartilage-trabecular bone junction in newborn rat femur","volume":"52","author":"Sawae","year":"2003","journal-title":"J Electron Microsc (Tokyo)"},{"key":"2020071611584947100_B100","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2008.08.130","article-title":"Bone density, strength, and formation in adult cathepsin K (\u2212\/\u2212) mice","volume":"44","author":"Pennypacker","year":"2009","journal-title":"Bone"},{"key":"2020071611584947100_B101","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1359\/jbmr.2003.18.5.859","article-title":"The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation","volume":"18","author":"Garnero","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B102","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00774-006-0725-9","article-title":"Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood","volume":"25","author":"S\u00f8rensen","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"2020071611584947100_B103","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2004.09.020","article-title":"Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL\/OPG ratio","volume":"36","author":"Kiviranta","year":"2005","journal-title":"Bone"},{"key":"2020071611584947100_B104","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bone.2007.07.010","article-title":"Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice","volume":"41","author":"Zenger","year":"2007","journal-title":"Bone"},{"key":"2020071611584947100_B105","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S8756-3282(01)00619-6","article-title":"Targeted and nontargeted remodeling","volume":"30","author":"Burr","year":"2002","journal-title":"Bone"},{"key":"2020071611584947100_B106","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S8756-3282(01)00642-1","article-title":"Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression","volume":"30","author":"Parfitt","year":"2002","journal-title":"Bone"},{"key":"2020071611584947100_B107","doi-asserted-by":"crossref","first-page":"46","DOI":"10.22203\/eCM.v006a05","article-title":"Bone microdamage and cell apoptosis","volume":"6","author":"Noble","year":"2003","journal-title":"Eur Cell Mater"},{"key":"2020071611584947100_B108","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1359\/jbmr.2000.15.1.60","article-title":"Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo","volume":"15","author":"Verborgt","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B109","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.cmet.2007.05.001","article-title":"Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction","volume":"5","author":"Tatsumi","year":"2007","journal-title":"Cell Metab"},{"key":"2020071611584947100_B110","first-page":"402","article-title":"Calcium homeostasis: solving the solubility problem","volume":"6","author":"Talmage","year":"2006","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2020071611584947100_B111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2003.05.002","article-title":"Misconceptions (3): calcium leaves bone only by resorption and enters only by formation","volume":"33","author":"Parfitt","year":"2003","journal-title":"Bone"},{"key":"2020071611584947100_B112","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bone.2005.04.036","article-title":"Bone as an ion exchange organ: evidence for instantaneous cell-dependent calcium efflux from bone not due to resorption","volume":"37","author":"Marenzana","year":"2005","journal-title":"Bone"},{"key":"2020071611584947100_B113","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/adc.40.209.7","article-title":"Studies in osteopetrosis","volume":"40","author":"Dent","year":"1965","journal-title":"Arch Dis Child"},{"key":"2020071611584947100_B114","first-page":"115","article-title":"Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis","volume":"21","author":"Manolagas","year":"2000","journal-title":"Endocr Rev"},{"key":"2020071611584947100_B115","doi-asserted-by":"crossref","first-page":"44975","DOI":"10.1074\/jbc.M303905200","article-title":"Transforming growth factor-\u03b2 controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression","volume":"278","author":"Karsdal","year":"2003","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B116","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1172\/JCI30328","article-title":"Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans","volume":"117","author":"Van Wesenbeeck","year":"2007","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B117","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1074\/jbc.M610536200","article-title":"Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation","volume":"282","author":"Valcourt","year":"2007","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B118","first-page":"476","article-title":"Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women","volume":"74","author":"Schlemmer","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B119","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s002239900497","article-title":"Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment","volume":"63","author":"Gertz","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B120","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S8756-3282(02)00791-3","article-title":"Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting","volume":"31","author":"Qvist","year":"2002","journal-title":"Bone"},{"key":"2020071611584947100_B121","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S8756-3282(01)00662-7","article-title":"Mechanism of circadian variation in bone resorption","volume":"30","author":"Bjarnason","year":"2002","journal-title":"Bone"},{"key":"2020071611584947100_B122","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-8-5","article-title":"Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of salmon calcitonin","volume":"8","author":"Karsdal","year":"2008","journal-title":"BMC Clin Pharmacol"},{"key":"2020071611584947100_B123","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2125.2009.03371.x","article-title":"Influence of food intake on the bioavailability and efficacy of oral calcitonin","volume":"67","author":"Karsdal","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"2020071611584947100_B124","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2003.09.009","article-title":"Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2","volume":"34","author":"Henriksen","year":"2004","journal-title":"Bone"},{"key":"2020071611584947100_B125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.bone.2006.09.025","article-title":"Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women","volume":"40","author":"Henriksen","year":"2007","journal-title":"Bone"},{"key":"2020071611584947100_B126","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bone.2009.07.008","article-title":"Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD","volume":"45","author":"Henriksen","year":"2009","journal-title":"Bone"},{"key":"2020071611584947100_B127","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1359\/JBMR.040715","article-title":"Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover","volume":"19","author":"Tank\u00f3","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B128","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B129","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00198-008-0731-y","article-title":"Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo","volume":"20","author":"Clowes","year":"2009","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00198-007-0452-7","article-title":"Estradiol rapidly inhibits osteoclastogenesis and RANKL expression in bone marrow cultures in postmenopausal women: a pilot study","volume":"19","author":"Taxel","year":"2008","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B131","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1359\/JBMR.050503","article-title":"Aging increases stromal\/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse","volume":"20","author":"Cao","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B132","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1096\/fj.04-2214fje","article-title":"Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis","volume":"19","author":"D'Amelio","year":"2005","journal-title":"FASEB J"},{"key":"2020071611584947100_B133","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/03009740310000102","article-title":"Osteoclast formation from circulating precursors in osteoporosis","volume":"32","author":"Jevon","year":"2003","journal-title":"Scand J Rheumatol"},{"key":"2020071611584947100_B134","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","article-title":"Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis","volume":"43","author":"D'Amelio","year":"2008","journal-title":"Bone"},{"key":"2020071611584947100_B135","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.130200197","article-title":"Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression","volume":"97","author":"Shevde","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B136","doi-asserted-by":"crossref","first-page":"8836","DOI":"10.1074\/jbc.M010764200","article-title":"Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-\u03baB ligand (RANKL)-induced JNK activation","volume":"276","author":"Srivastava","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B137","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/dna.2006.25.475","article-title":"Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts","volume":"25","author":"S\u00f8rensen","year":"2006","journal-title":"DNA Cell Biol"},{"key":"2020071611584947100_B138","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1210\/endo.142.9.8402","article-title":"Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor","volume":"142","author":"Huber","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611584947100_B139","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor \u03b1 and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"2020071611584947100_B140","first-page":"2309","article-title":"Estrogen receptors \u03b1 and \u03b2 are differentially expressed in developing human bone","volume":"86","author":"Bord","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B141","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1210\/me.2009-0354","article-title":"The estrogen receptor-\u03b1 in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone","volume":"24","author":"Martin-Millan","year":"2010","journal-title":"Mol Endocrinol"},{"key":"2020071611584947100_B142","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1359\/jbmr.040916","article-title":"Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites","volume":"19","author":"Riggs","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B143","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1359\/JBMR.040710","article-title":"Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients","volume":"19","author":"Recker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B144","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01880415","article-title":"Trabecular and endocortical bone remodeling in postmenopausal osteoporosis: comparison with normal postmenopausal women","volume":"1","author":"Arlot","year":"1990","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B146","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00198-005-2035-9","article-title":"The role of collagen in bone strength","volume":"17","author":"Viguet-Carrin","year":"2006","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B147","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1373\/clinchem.2005.053363","article-title":"Increased osteoclast activity in the presence of increased homocysteine concentrations","volume":"51","author":"Herrmann","year":"2005","journal-title":"Clin Chem"},{"key":"2020071611584947100_B148","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00198-009-1066-z","article-title":"Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus","volume":"21","author":"Saito","year":"2010","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B149","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1681\/ASN.V82260","article-title":"Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles","volume":"8","author":"Miyata","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"2020071611584947100_B150","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1210\/jc.2008-2498","article-title":"Pentosidine and increased fracture risk in older adults with type 2 diabetes","volume":"94","author":"Schwartz","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B151","first-page":"137","article-title":"The impact of diabetes mellitus on skeletal health: an established phenomenon with inestablished causes?","volume":"106","author":"Raska","year":"2005","journal-title":"Prague Med Rep"},{"key":"2020071611584947100_B152","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1196\/annals.1433.044","article-title":"Pentosidine effects on human osteoblasts in vitro","volume":"1126","author":"Sanguineti","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"2020071611584947100_B153","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbrc.2008.11.145","article-title":"Characterization of acid flux in osteoclasts from patients harboring a G215R mutation in ClC-7","volume":"378","author":"Henriksen","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071611584947100_B154","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0002-9440(10)63798-4","article-title":"Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis","volume":"162","author":"Taranta","year":"2003","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B155","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1359\/jbmr.071015","article-title":"Clinical and cellular manifestations of OSTM1-related infantile osteopetrosis","volume":"23","author":"Maranda","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B156","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S8756-3282(01)00416-1","article-title":"The mouse osteopetrotic grey-lethal mutation induces a defect in osteoclast maturation\/function","volume":"28","author":"Rajapurohitam","year":"2001","journal-title":"Bone"},{"key":"2020071611584947100_B157","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S8756-3282(00)00330-6","article-title":"Higher osteoclastic demineralization and highly mineralized cement lines with osteocalcin deposition in a mandibular cortical bone of autosomal dominant osteopetrosis type II: ultrastructural and undecalcified histological investigations","volume":"27","author":"Semba","year":"2000","journal-title":"Bone"},{"key":"2020071611584947100_B158","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","article-title":"Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone","volume":"62","author":"Garnero","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B159","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.bbrc.2007.06.145","article-title":"Dissolution of the inorganic phase of bone leading to release of calcium regulates osteoclast survival","volume":"360","author":"Nielsen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071611584947100_B160","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1373\/clinchem.2003.029355","article-title":"Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis)","volume":"50","author":"Alatalo","year":"2004","journal-title":"Clin Chem"},{"key":"2020071611584947100_B161","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/jmg.2005.036673","article-title":"Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment","volume":"43","author":"Del Fattore","year":"2006","journal-title":"J Med Genet"},{"key":"2020071611584947100_B162","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0092-8674(91)90499-O","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"Soriano","year":"1991","journal-title":"Cell"},{"key":"2020071611584947100_B163","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.7939685","article-title":"c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling","volume":"266","author":"Grigoriadis","year":"1994","journal-title":"Science"},{"key":"2020071611584947100_B164","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased c-Src expression enhances osteoblast differentiation and bone formation","volume":"151","author":"Marzia","year":"2000","journal-title":"J Cell Biol"},{"key":"2020071611584947100_B165","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1210\/en.2002-220221","article-title":"Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos","volume":"143","author":"Demiralp","year":"2002","journal-title":"Endocrinology"},{"key":"2020071611584947100_B166","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1210\/en.2005-0333","article-title":"Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone","volume":"146","author":"Koh","year":"2005","journal-title":"Endocrinology"},{"key":"2020071611584947100_B167","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1074\/jbc.M501900200","article-title":"Essential role of \u03b2-catenin in postnatal bone acquisition","volume":"280","author":"Holmen","year":"2005","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B168","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"2020071611584947100_B169","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1086\/368277","article-title":"Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density","volume":"72","author":"Van Wesenbeeck","year":"2003","journal-title":"Am J Hum Genet"},{"key":"2020071611584947100_B170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1615\/CritRevEukaryotGeneExpr.v13.i24.90","article-title":"Serum levels of TGF-\u03b2 and fibronectin in autosomal dominant osteopetrosis in relation to underlying mutations and well-described murine counterparts","volume":"13","author":"Bollerslev","year":"2003","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"2020071611584947100_B171","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00003086-197101000-00035","article-title":"Tetracycline-based study of bone dynamics in pycnodysostosis","volume":"74","author":"Sarnsethsiri","year":"1971","journal-title":"Clin Orthop Relat Res"},{"key":"2020071611584947100_B172","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1359\/jbmr.1999.14.10.1649","article-title":"Mutations of CTSK result in pycnodysostosis via a reduction in cathepsin K protein","volume":"14","author":"Ho","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B173","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1172\/JCI653","article-title":"Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pycnodysostosis","volume":"103","author":"Hou","year":"1999","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B174","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1359\/jbmr.080231","article-title":"Mechanisms of the anabolic effects of teriparatide on bone: insight from the treatment of a patient with pycnodysostosis","volume":"23","author":"Chavassieux","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/BF02557674","article-title":"Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis","volume":"37","author":"Everts","year":"1985","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B176","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1359\/jbmr.060313","article-title":"Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass","volume":"21","author":"Li","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B177","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/jc.2003-031055","article-title":"Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis","volume":"89","author":"Fratzl-Zelman","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B178","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B179","first-page":"1171","article-title":"Effects of odanacatib on central femur cortical bone in estrogen-deficient adult rhesus monkeys","volume":"24","author":"Pennypacker","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B180","first-page":"FR0416","article-title":"Effects of odanacatib on bone mass, turnover and strength in the femoral neck of estrogen deficient adult rhesus monkeys","volume":"24","author":"Cusick","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B181","first-page":"SU0227","article-title":"Effects of odanacatib on bone turnover and osteoclast morphology in the lumbar vertebra of ovariectomized adult rhesus monkeys","volume":"24","author":"Scott","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B182","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1138\/20060249","article-title":"The pathogenesis of osteoclast diseases: some knowns, but still many unknowns","volume":"4","author":"Helfrich","year":"2007","journal-title":"BoneKEy-Osteovision"},{"key":"2020071611584947100_B183","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/8756-3282(96)00211-6","article-title":"Paget's disease and osteoclast biology","volume":"19","author":"Roodman","year":"1996","journal-title":"Bone"},{"key":"2020071611584947100_B184","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/jcp.2009.064428","article-title":"Recent advances in understanding the molecular basis of Paget's disease of bone","volume":"63","author":"Goode","year":"2010","journal-title":"J Clin Pathol"},{"key":"2020071611584947100_B185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1172\/JCI24281","article-title":"Paget disease of bone","volume":"115","author":"Roodman","year":"2005","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B186","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(08)61035-1","article-title":"Pathogenesis and management of Paget's disease of bone","volume":"372","author":"Ralston","year":"2008","journal-title":"Lancet"},{"key":"2020071611584947100_B187","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S8756-3282(00)00345-8","article-title":"Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL","volume":"27","author":"Neale","year":"2000","journal-title":"Bone"},{"key":"2020071611584947100_B188","doi-asserted-by":"crossref","first-page":"P51","DOI":"10.1359\/jbmr.06s209","article-title":"Ultrastructure of bone cells in Paget's disease of bone","volume":"21","author":"Singer","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B189","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1172\/JCI28267","article-title":"Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease","volume":"117","author":"Kurihara","year":"2007","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B190","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1093\/hmg\/ddn266","article-title":"A SQSTM1\/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment","volume":"17","author":"Hiruma","year":"2008","journal-title":"Hum Mol Genet"},{"key":"2020071611584947100_B191","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.2174\/138955709788922683","article-title":"The use of intravenous aminobisphosphonates for the treatment of Paget's disease of bone","volume":"9","author":"Gennari","year":"2009","journal-title":"Mini Rev Med Chem"},{"key":"2020071611584947100_B192","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/S1462399408000616","article-title":"Molecular mechanisms and treatment of bone metastasis","volume":"10","author":"Clines","year":"2008","journal-title":"Expert Rev Mol Med"},{"key":"2020071611584947100_B193","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","article-title":"Basic mechanisms responsible for osteolytic and osteoblastic bone metastases","volume":"12","author":"Guise","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2020071611584947100_B194","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11926-010-0098-x","article-title":"Cancer therapies and bone health","volume":"12","author":"Hu","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"2020071611584947100_B195","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/cbt.7.1.5163","article-title":"Biology of breast cancer bone metastasis","volume":"7","author":"Akhtari","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"2020071611584947100_B196","doi-asserted-by":"crossref","first-page":"6305s","DOI":"10.1158\/1078-0432.CCR-06-1157","article-title":"Future treatment of bone metastases","volume":"12","author":"Lipton","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2020071611584947100_B197","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10585-007-9112-8","article-title":"Bone metastasis: pathogenesis and therapeutic implications","volume":"24","author":"Clezardin","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"2020071611584947100_B198","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s10555-006-9035-x","article-title":"Breast cancer bone metastasis and current small therapeutics","volume":"25","author":"Cicek","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"2020071611584947100_B199","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/1055-9965.EPI-05-0492","article-title":"The relative use of eight collagenous and noncollagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020071611584947100_B200","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1158\/1055-9965.EPI-05-0909","article-title":"\u03b1 CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion","volume":"15","author":"Leeming","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2020071611584947100_B201","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J Urol"},{"key":"2020071611584947100_B202","first-page":"1932","article-title":"Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice","volume":"8","author":"Winding","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2020071611584947100_B203","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/SPC.0b013e32830baea9","article-title":"Cathepsin K inhibitors as treatment of bone metastasis","volume":"2","author":"Le Gall","year":"2008","journal-title":"Curr Opin Support Palliat Care"},{"key":"2020071611584947100_B204","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1158\/0008-5472.CAN-06-3940","article-title":"A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden","volume":"67","author":"Le Gall","year":"2007","journal-title":"Cancer Res"},{"key":"2020071611584947100_B205","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1126\/science.1067100","article-title":"Matrix metalloproteinase inhibitors and cancer: trials and tribulations","volume":"295","author":"Coussens","year":"2002","journal-title":"Science"},{"key":"2020071611584947100_B206","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1023047431869","article-title":"Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials","volume":"22","author":"Pavlaki","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"2020071611584947100_B207","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/SPC.0b013e32832f4149","article-title":"New results from the use of bisphosphonates in cancer patients","volume":"3","author":"Coleman","year":"2009","journal-title":"Curr Opin Support Palliat Care"},{"key":"2020071611584947100_B208","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"2020071611584947100_B209","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2020071611584947100_B210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"2020071611584947100_B211","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2009.06.003","article-title":"Zoledronic acid induces apoptosis and changes the TRAIL\/OPG ratio in breast cancer cells","volume":"287","author":"Rachner","year":"2010","journal-title":"Cancer Lett"},{"key":"2020071611584947100_B212","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1359\/jbmr.090533","article-title":"Osteoclasts and arthritis","volume":"24","author":"Schett","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B213","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar2166","article-title":"Erosive arthritis","volume":"9","author":"Schett","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2020071611584947100_B214","first-page":"943","article-title":"Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis","volume":"152","author":"Gravallese","year":"1998","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B215","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu Rev Immunol"},{"key":"2020071611584947100_B216","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1002\/j.1460-2075.1991.tb04978.x","article-title":"Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis","volume":"10","author":"Keffer","year":"1991","journal-title":"EMBO J"},{"key":"2020071611584947100_B217","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1503\/cmaj.091391","article-title":"A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview","volume":"181","author":"Singh","year":"2009","journal-title":"CMAJ"},{"key":"2020071611584947100_B218","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/039463200902200302","article-title":"Tumor necrosis factor-\u03b1 antagonists: differential clinical effects by different biotechnological molecules","volume":"22","author":"Licastro","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2020071611584947100_B219","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0002-9440(10)63016-7","article-title":"TRANCE\/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis","volume":"159","author":"Pettit","year":"2001","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B220","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0002-9440(10)64417-3","article-title":"Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis","volume":"161","author":"Romas","year":"2002","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B221","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","article-title":"Osteoclasts are essential for TNF-\u03b1-mediated joint destruction","volume":"110","author":"Redlich","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B222","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B223","doi-asserted-by":"crossref","first-page":"11742","DOI":"10.1073\/pnas.0610812104","article-title":"TNF-induced structural joint damage is mediated by IL-1","volume":"104","author":"Zwerina","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B224","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/art.21824","article-title":"Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis","volume":"54","author":"Jarrett","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B225","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jbspin.2005.10.019","article-title":"Bisphosphonate therapy in rheumatoid arthritis","volume":"73","author":"Breuil","year":"2006","journal-title":"Joint Bone Spine"},{"key":"2020071611584947100_B226","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s00198-005-0037-2","article-title":"Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial","volume":"17","author":"Lems","year":"2006","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B227","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(09)60250-6","article-title":"Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"373","author":"Reid","year":"2009","journal-title":"Lancet"},{"key":"2020071611584947100_B228","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.20382","article-title":"Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis","volume":"50","author":"Sims","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B229","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/art.20384","article-title":"Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis","volume":"50","author":"Herrak","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B230","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/ard.2002.004671","article-title":"Up regulation of cathepsin K expression in articular chondrocytes in a transgenic mouse model for osteoarthritis","volume":"63","author":"Morko","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2020071611584947100_B231","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1002\/art.21423","article-title":"Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K","volume":"52","author":"Morko","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B232","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/art.23224","article-title":"Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice","volume":"58","author":"Schurigt","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B233","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0002-9440(10)63068-4","article-title":"Cathepsin K is a critical protease in synovial fibroblast-mediated collagen degradation","volume":"159","author":"Hou","year":"2001","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B234","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.addr.2004.12.013","article-title":"The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics","volume":"57","author":"Yasuda","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"2020071611584947100_B235","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1002\/art.23996","article-title":"Erosive arthritis in a patient with pycnodysostosis: an experiment of nature","volume":"58","author":"Ainola","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B236","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2009.03.074","article-title":"Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice","volume":"613","author":"Svelander","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"2020071611584947100_B237","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/138945007779940188","article-title":"Role of cathepsin K in normal joints and in the development of arthritis","volume":"8","author":"Salminen-Mankonen","year":"2007","journal-title":"Curr Drug Targets"},{"key":"2020071611584947100_B238","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1080\/03009740701753689","article-title":"Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression","volume":"37","author":"Hakala","year":"2008","journal-title":"Scand J Rheumatol"},{"key":"2020071611584947100_B239","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1515\/CCLM.2003.160","article-title":"Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis","volume":"41","author":"Sassi","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"2020071611584947100_B240","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","volume":"67","author":"Chopin","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2020071611584947100_B241","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/s10165-009-0208-7","article-title":"Rheumatoid arthritis associated with osteopetrosis","volume":"19","author":"Kadono","year":"2009","journal-title":"Mod Rheumatol"},{"key":"2020071611584947100_B242","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B243","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1172\/JCI119668","article-title":"Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis","volume":"100","author":"Chavassieux","year":"1997","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B244","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00198-003-1530-0","article-title":"Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study","volume":"15","author":"Recker","year":"2004","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B245","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1359\/jbmr.070906","article-title":"Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure","volume":"23","author":"Recker","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B246","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1359\/JBMR.050403","article-title":"Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover","volume":"20","author":"Nenonen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B247","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bone.2003.04.002","article-title":"Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption","volume":"34","author":"Hannon","year":"2004","journal-title":"Bone"},{"key":"2020071611584947100_B248","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.maturitas.2009.09.011","article-title":"Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate","volume":"64","author":"Mu\u00f1oz-Torres","year":"2009","journal-title":"Maturitas"},{"key":"2020071611584947100_B249","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1359\/jbmr.071031","article-title":"Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women","volume":"23","author":"D'Amelio","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B250","article-title":"December 2009 Alendronate reduces osteoclast precursors in osteoporosis","author":"D'Amelio","year":"1","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B251","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1056\/NEJMoa0802633","article-title":"Giant osteoclast formation and long-term oral bisphosphonate therapy","volume":"360","author":"Weinstein","year":"2009","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B252","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S8756-3282(97)00200-7","article-title":"Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures","volume":"21","author":"Mori","year":"1997","journal-title":"Bone"},{"key":"2020071611584947100_B253","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B254","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1359\/jbmr.080307","article-title":"Low bone turnover and microdamage? How and where to assess it?","volume":"23","author":"Burr","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B255","first-page":"2363","article-title":"Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study","volume":"84","author":"Ravn","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B256","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"2020071611584947100_B257","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S8756-3282(03)00168-6","article-title":"Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis","volume":"33","author":"Ravn","year":"2003","journal-title":"Bone"},{"key":"2020071611584947100_B258","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S8756-3282(02)00869-4","article-title":"Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis","volume":"31","author":"Eriksen","year":"2002","journal-title":"Bone"},{"key":"2020071611584947100_B259","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"2020071611584947100_B260","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B261","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2009-1947","article-title":"Long-term use of bisphosphonates in osteoporosis","volume":"95","author":"Watts","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B262","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B263","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1111\/j.1834-7819.2009.01143.x","article-title":"Alveolar bone and the bisphosphonates","volume":"54","author":"Cheng","year":"2009","journal-title":"Aust Dent J"},{"key":"2020071611584947100_B264","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ar.1092020403","article-title":"Cellular kinetics of the bone remodeling sequence in the rat","volume":"202","author":"Tran Van","year":"1982","journal-title":"Anat Rec"},{"key":"2020071611584947100_B265","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/BF00214682","article-title":"An electron-microscopic study of the bone-remodeling sequence in the rat","volume":"225","author":"Tran Van","year":"1982","journal-title":"Cell Tissue Res"},{"key":"2020071611584947100_B266","first-page":"363","article-title":"Kinetic and cytochemical identification of osteoclast precursors and their differentiation into multinucleated osteoclasts","volume":"122","author":"Baron","year":"1986","journal-title":"Am J Pathol"},{"key":"2020071611584947100_B267","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bone.2009.05.008","article-title":"Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy","volume":"45","author":"Favia","year":"2009","journal-title":"Bone"},{"key":"2020071611584947100_B268","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.tripleo.2007.08.040","article-title":"Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology","volume":"105","author":"Bedogni","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"2020071611584947100_B269","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med"},{"key":"2020071611584947100_B270","first-page":"39","article-title":"Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures","volume":"13","author":"Ramalho","year":"2002","journal-title":"Eur Cytokine Netw"},{"key":"2020071611584947100_B271","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/jcp.10406","article-title":"17\u03b2-Estradiol downregulates \u03b23-integrin expression in differentiating and mature human osteoclasts","volume":"198","author":"Saintier","year":"2004","journal-title":"J Cell Physiol"},{"key":"2020071611584947100_B272","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1359\/JBMR.050803","article-title":"Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption","volume":"20","author":"Michael","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B273","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.bjp.0707232","article-title":"Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro","volume":"151","author":"Michael","year":"2007","journal-title":"Br J Pharmacol"},{"key":"2020071611584947100_B274","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S8756-3282(01)00685-8","article-title":"The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro","volume":"30","author":"Taranta","year":"2002","journal-title":"Bone"},{"key":"2020071611584947100_B275","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1073\/pnas.88.15.6613","article-title":"Avian osteoclasts as estrogen target cells","volume":"88","author":"Oursler","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B276","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1073\/pnas.91.12.5227","article-title":"Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells","volume":"91","author":"Oursler","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B277","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1210\/endo.132.3.8440193","article-title":"Estrogen modulation of avian osteoclast lysosomal gene expression","volume":"132","author":"Oursler","year":"1993","journal-title":"Endocrinology"},{"key":"2020071611584947100_B278","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jcb.240570211","article-title":"Estrogen modulation of osteoclast lysosomal enzyme secretion","volume":"57","author":"Kremer","year":"1995","journal-title":"J Cell Biochem"},{"key":"2020071611584947100_B279","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1210\/endo.142.12.8533","article-title":"Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts","volume":"142","author":"Parikka","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611584947100_B280","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1359\/jbmr.2002.17.2.341","article-title":"Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women","volume":"17","author":"Ott","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B281","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/8756-3282(89)90126-9","article-title":"A randomized study on the effects of estrogen\/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis","volume":"10","author":"Steiniche","year":"1989","journal-title":"Bone"},{"key":"2020071611584947100_B282","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S8756-3282(98)00177-X","article-title":"Early effects of hormone replacement therapy on bone","volume":"24","author":"Patel","year":"1999","journal-title":"Bone"},{"key":"2020071611584947100_B283","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1359\/jbmr.1999.14.7.1217","article-title":"Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women","volume":"14","author":"Eriksen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B284","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s001980050194","article-title":"Bone remodeling and structure in postmenopausal women treated with long-term, high-dose estrogen therapy","volume":"10","author":"Vedi","year":"1999","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B285","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"2020071611584947100_B286","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s001980050236","article-title":"Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group","volume":"10","author":"Meunier","year":"1999","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B287","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1359\/jbmr.1998.13.11.1747","article-title":"Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial","volume":"13","author":"Lufkin","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B288","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jcem-57-4-819","article-title":"The sensitivity of isolated osteoclasts to morphological transformation by calcitonin","volume":"57","author":"Chambers","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B289","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1210\/endo.137.11.8895334","article-title":"Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts","volume":"137","author":"Suzuki","year":"1996","journal-title":"Endocrinology"},{"key":"2020071611584947100_B290","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.bone.2007.01.014","article-title":"Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities","volume":"40","author":"Shyu","year":"2007","journal-title":"Bone"},{"key":"2020071611584947100_B291","article-title":"Lessons learned from the development of oral calcitonin: the first tablet formulation of a peptide in phase III clinical trials","author":"Karsdal","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"2020071611584947100_B292","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6904-8-12","article-title":"Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin","volume":"8","author":"Karsdal","year":"2008","journal-title":"BMC Clin Pharmacol"},{"key":"2020071611584947100_B293","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1185\/030079906X104768","article-title":"A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study","volume":"22","author":"Kung","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"2020071611584947100_B294","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-005-2002-5","article-title":"Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis","volume":"17","author":"Hwang","year":"2006","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B295","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1359\/jbmr.2002.17.3.521","article-title":"A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers","volume":"17","author":"Trovas","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B296","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1359\/JBMR.050411","article-title":"Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study","volume":"20","author":"Chesnut","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B297","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bone.2004.03.018","article-title":"Calcitonin-induced change in serum calcium levels and its relationship to osteoclast morphology and number of calcitonin receptors","volume":"35","author":"Ikegame","year":"2004","journal-title":"Bone"},{"key":"2020071611584947100_B298","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1359\/JBMR.041008","article-title":"Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation","volume":"20","author":"Jiang","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B299","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1172\/JCI200214218","article-title":"Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene","volume":"110","author":"Hoff","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B300","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1083\/jcb.200312135","article-title":"Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo","volume":"164","author":"Dacquin","year":"2004","journal-title":"J Cell Biol"},{"key":"2020071611584947100_B301","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1359\/jbmr.080310","article-title":"Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice","volume":"23","author":"Davey","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B302","first-page":"1049","article-title":"The calcitonin receptor expressed by osteoclasts plays a biological role to protect against induced hypercalcemia in mice","volume":"24","author":"Turner","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B303","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00198-008-0603-5","article-title":"The effects of oral calcitonin on bone collagen maturation: implications for bone turnover and quality","volume":"19","author":"Karsdal","year":"2008","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B304","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF02441175","article-title":"Time-related changes in the ultrastructure of osteoclasts after injection of parathyroid hormone in young rats","volume":"27","author":"Holtrop","year":"1979","journal-title":"Calcif Tissue Int"},{"key":"2020071611584947100_B305","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"key":"2020071611584947100_B306","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S8756-3282(00)00316-1","article-title":"Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1\u201334) therapy in women with severe osteoporosis","volume":"27","author":"Hodsman","year":"2000","journal-title":"Bone"},{"key":"2020071611584947100_B307","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1359\/JBMR.050309","article-title":"Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters","volume":"20","author":"Arlot","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B308","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.090315","article-title":"Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis","volume":"24","author":"Recker","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B309","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1210\/endo.136.8.7628403","article-title":"Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells","volume":"136","author":"Dobnig","year":"1995","journal-title":"Endocrinology"},{"key":"2020071611584947100_B310","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B311","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1359\/jbmr.090413","article-title":"Intermittent PTH administration stimulates pre-osteoblastic proliferation without leading to enhanced bone formation in osteoclast-less c-fos(\u2212\/\u2212) mice","volume":"24","author":"Luiz de Freitas","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B312","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B313","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B314","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1359\/jbmr.040117","article-title":"Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate","volume":"19","author":"Ettinger","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B315","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1210\/en.2007-0229","article-title":"The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL\/6J mice","volume":"148","author":"Johnston","year":"2007","journal-title":"Endocrinology"},{"key":"2020071611584947100_B316","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1359\/jbmr.060915","article-title":"Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice","volume":"22","author":"Samadfam","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B317","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B318","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1359\/jbmr.060404","article-title":"Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older","volume":"21","author":"Seeman","year":"2006","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B319","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B320","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.bone.2009.12.006","article-title":"Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age","volume":"46","author":"Seeman","year":"2010","journal-title":"Bone"},{"key":"2020071611584947100_B321","doi-asserted-by":"crossref","first-page":"iv20","DOI":"10.1093\/rheumatology\/kep276","article-title":"Continuous broad protection against osteoporotic fractures with strontium ranelate","volume":"48","author":"Ferrari","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2020071611584947100_B322","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1359\/jbmr.071012","article-title":"Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate","volume":"23","author":"Arlot","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B323","first-page":"2060","article-title":"Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis\u2014a 2-year randomized placebo controlled trial","volume":"87","author":"Meunier","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B324","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/art.24781","article-title":"Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo","volume":"60","author":"Axmann","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B325","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00198-009-1078-8","article-title":"Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years","volume":"21","author":"Bruy\u00e8re","year":"2010","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B326","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bone.2007.08.043","article-title":"Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro","volume":"42","author":"Bonnelye","year":"2008","journal-title":"Bone"},{"key":"2020071611584947100_B327","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(96)00080-4","article-title":"The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro","volume":"18","author":"Canalis","year":"1996","journal-title":"Bone"},{"key":"2020071611584947100_B328","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1359\/jbmr.2003.18.6.1082","article-title":"S 12911\u20132 inhibits osteoclastic bone resorption in vitro","volume":"18","author":"Takahashi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B329","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1074\/jbc.M801668200","article-title":"The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways","volume":"284","author":"Hurtel-Lemaire","year":"2009","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B330","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/j.1476-5381.2009.00305.x","article-title":"Osteoblasts play key roles in the mechanisms of action of strontium ranelate","volume":"157","author":"Brennan","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2020071611584947100_B331","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar2542","article-title":"Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study","volume":"10","author":"Engvall","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"2020071611584947100_B332","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1517\/14740330802648194","article-title":"Glucocorticoids and the risk of osteoporosis","volume":"8","author":"Caplan","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"2020071611584947100_B333","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","article-title":"Glucocorticoid-induced osteoporosis: pathophysiology and therapy","volume":"18","author":"Canalis","year":"2007","journal-title":"Osteoporos Int"},{"key":"2020071611584947100_B334","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1517\/14656560902868225","article-title":"Prevention of glucocorticoid-induced osteoporosis","volume":"10","author":"van Brussel","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"2020071611584947100_B335","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B336","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/art.24445","article-title":"Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL","volume":"60","author":"Hofbauer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B337","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","article-title":"Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density","volume":"147","author":"Jia","year":"2006","journal-title":"Endocrinology"},{"key":"2020071611584947100_B338","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/art.23454","article-title":"Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice","volume":"58","author":"Yao","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2020071611584947100_B339","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI0214538","article-title":"Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids","volume":"109","author":"Weinstein","year":"2002","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B340","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI28084","article-title":"Glucocorticoids suppress bone formation via the osteoclast","volume":"116","author":"Kim","year":"2006","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B341","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1359\/JBMR.041233","article-title":"Influence of glucocorticoids on human osteoclast generation and activity","volume":"20","author":"Sivagurunathan","year":"2005","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B342","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"2020071611584947100_B343","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1189\/jlb.1106673","article-title":"6-Methylprednisolone down-regulates IRAK-M in human and murine osteoclasts and boosts bone-resorbing activity: a putative mechanism for corticoid-induced osteoporosis","volume":"82","author":"Soares-Schanoski","year":"2007","journal-title":"J Leukoc Biol"},{"key":"2020071611584947100_B344","article-title":"April 2010 Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle","author":"S\u00f8e","year":"30","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B345","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1210\/jc.2004-0164","article-title":"Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis","volume":"89","author":"Dovio","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B346","first-page":"28","article-title":"Biochemical markers in glucocorticoid-induced osteoporosis","volume":"31","author":"Minisola","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"2020071611584947100_B347","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.micron.2005.07.009","article-title":"Histomorphometric analysis of glucocorticoid-induced osteoporosis","volume":"36","author":"Dalle Carbonare","year":"2005","journal-title":"Micron"},{"key":"2020071611584947100_B348","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/gut.29.3.378","article-title":"Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis","volume":"29","author":"Stellon","year":"1988","journal-title":"Gut"},{"key":"2020071611584947100_B349","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.3899\/jrheum.081207","article-title":"Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial","volume":"36","author":"Stoch","year":"2009","journal-title":"J Rheumatol"},{"key":"2020071611584947100_B350","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1359\/jbmr.2002.17.9.1570","article-title":"Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone","volume":"17","author":"Bikle","year":"2002","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B351","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B352","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1359\/jbmr.081112","article-title":"Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine\/human) RANKL","volume":"24","author":"Kostenuik","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B353","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071611584947100_B354","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"2020071611584947100_B355","first-page":"S126","article-title":"Decreased bone turnover and porosity are associated with improved bone strength in ovariectomized (OVX) cynomolgus monkeys treated with denosumab, a fully human RANKL antibody","volume":"22","author":"Ominsky","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B356","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S8756-3282(00)00235-0","article-title":"Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K","volume":"26","author":"Sassi","year":"2000","journal-title":"Bone"},{"key":"2020071611584947100_B357","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bone.2007.09.044","article-title":"Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts","volume":"42","author":"Fuller","year":"2008","journal-title":"Bone"},{"key":"2020071611584947100_B358","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/jemt.20813","article-title":"The cathepsin K inhibitor AAE581 induces morphological changes in osteoclasts of treated patients","volume":"73","author":"Chappard","year":"2010","journal-title":"Microsc Res Tech"},{"key":"2020071611584947100_B359","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/03008200390181717","article-title":"Mechanisms by which extracellular matrix components induce osteoblast apoptosis","volume":"44","author":"Adams","year":"2003","journal-title":"Connect Tissue Res"},{"key":"2020071611584947100_B360","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1359\/jbmr.080706","article-title":"Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling","volume":"23","author":"Walker","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B361","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/00365520802200028","article-title":"Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome","volume":"43","author":"Gottschalck","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"2020071611584947100_B362","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/00365520801965381","article-title":"Reduction in bone resorption by exogenous glucagon-like peptide-2 administration requires an intact gastrointestinal tract","volume":"43","author":"Gottschalck","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"2020071611584947100_B363","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1359\/jbmr.070613","article-title":"Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption","volume":"22","author":"S\u00f8rensen","year":"2007","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B364","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1359\/JBMR.040302","article-title":"The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation","volume":"19","author":"Schaller","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B365","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1172\/JCI6145","article-title":"A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats","volume":"106","author":"Visentin","year":"2000","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B366","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00001665-200305000-00007","article-title":"Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth","volume":"14","author":"Rzeszutek","year":"2003","journal-title":"J Craniofac Surg"},{"key":"2020071611584947100_B367","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dnp.2005.18.8.944546","article-title":"The role of chloride channels in osteoclasts: ClC-7 as a target for osteoporosis treatment","volume":"18","author":"Schaller","year":"2005","journal-title":"Drug News Perspect"},{"key":"2020071611584947100_B368","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-4020-6191-2_6","article-title":"The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics","volume":"45","author":"Brown","year":"2007","journal-title":"Subcell Biochem"},{"key":"2020071611584947100_B369","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1172\/JCI26239","article-title":"Osteoblast-derived PTHrP is a physiological regulator of bone formation","volume":"115","author":"Martin","year":"2005","journal-title":"J Clin Invest"},{"key":"2020071611584947100_B370","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.tem.2009.12.002","article-title":"Does osteocytic SOST suppression mediate PTH bone anabolism?","volume":"21","author":"Kramer","year":"2010","journal-title":"Trends Endocrinol Metab"},{"key":"2020071611584947100_B371","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/endo-97-2-283","article-title":"Increases in number and size of osteoclasts in response to calcium or phosphorus deficiency in the rat","volume":"97","author":"Thompson","year":"1975","journal-title":"Endocrinology"},{"key":"2020071611584947100_B372","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1073\/pnas.78.5.3204","article-title":"Parathyroid hormone stimulates bone formation and resorption in organ culture: evidence for a coupling mechanism","volume":"78","author":"Howard","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020071611584947100_B373","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/8756-3282(94)90282-8","article-title":"Regional variation of insulin-like growth factor-I gene expression in mature rat bone and cartilage","volume":"15","author":"Lazowski","year":"1994","journal-title":"Bone"},{"key":"2020071611584947100_B374","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1210\/endo.137.2.8593810","article-title":"Osteoclasts and transforming growth factor-\u03b2: estrogen-mediated isoform-specific regulation of production","volume":"137","author":"Robinson","year":"1996","journal-title":"Endocrinology"},{"key":"2020071611584947100_B375","doi-asserted-by":"crossref","first-page":"39350","DOI":"10.1074\/jbc.M008738200","article-title":"Transforming growth factor-\u03b2-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway","volume":"276","author":"Karsdal","year":"2001","journal-title":"J Biol Chem"},{"key":"2020071611584947100_B376","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.1990.tb16102.x","article-title":"Role of TGF \u03b2 in bone remodeling","volume":"593","author":"Mundy","year":"1990","journal-title":"Ann NY Acad Sci"},{"key":"2020071611584947100_B377","doi-asserted-by":"crossref","first-page":"S565","DOI":"10.1002\/jbmr.5650081326","article-title":"Growth factors to stimulate bone formation","volume":"8","author":"Baylink","year":"1993","journal-title":"J Bone Miner Res"},{"key":"2020071611584947100_B378","doi-asserted-by":"crossref","first-page":"93S","DOI":"10.1016\/8756-3282(95)00186-H","article-title":"The insulin-like growth factor system and the coupling of formation to resorption","volume":"17","author":"Hayden","year":"1995","journal-title":"Bone"},{"key":"2020071611584947100_B379","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/er.2004-0001","article-title":"Transforming growth factor-\u03b21 to the bone","volume":"26","author":"Janssens","year":"2005","journal-title":"Endocr Rev"},{"key":"2020071611584947100_B380","doi-asserted-by":"crossref","first-page":"44005","DOI":"10.1074\/jbc.M208265200","article-title":"Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization","volume":"277","author":"Zhang","year":"2002","journal-title":"J Biol Chem"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/32\/1\/31\/10335139\/edrv0031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/32\/1\/31\/10335139\/edrv0031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T23:11:36Z","timestamp":1712185896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/32\/1\/31\/2354819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":380,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2010-0006","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,1]]}}}